Please note: This is a recommendation to authorities and physicians. Patients are asked to consult a doctor.
SPR has updated its Covid-19 early treatment protocol and has added bromhexine. Bromhexine is a simple over-the-counter mucolytic cough medication that inhibits cellular TMPRSS2 protease and thus blocks SARS-CoV-2 cell entry via ACE2 cell receptors.
Several groups have already proposed bromhexine as an early or prophylactic treatment for Covid-19. An Iranian group recently reported a decrease in intensive care treatments of 82%, a decrease in intubations of 89%, and a decrease in deaths of 100% in a trial with 78 patients.
For further information on bromhexine see the reference section on the protocol page.
In view of a possible renewed increase in infection rates, early or prophylactic treatment of people at high risk or high exposure (including health care workers) should be of paramount importance to reduce hospitalizations and deaths.
EN: On the treatment of Covid-19 →
DE: Zur Behandlung von Covid-19 →
Source